| Name | Title | Contact Details |
|---|---|---|
Steven Yannelli |
Director of Application Security and Compliance | Profile |
Macrocure Ltd. is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Our novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body`s own wound healing and regenerative components directly into the wound itself.
Sunovion Pharmaceuticals Inc. leads the way to a healthier tomorrow by creating medicines for respiratory diseases and central nervous system disorders.
Pro Med Pharmacies, Inc is a Amarillo, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Were a community organization that emphasizes creativity and innovation to fill the gaps in wellness services in the Twin Cities area!
PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT`s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient`s cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens. PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient`s own blood to produce PACT`s therapeutic product: a tsunami of fresh, active T cells that, following infusion into the patient, recognize and attack each patient`s cancer cells.